Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway. In heart failure, there is reduced bioavailability of nitric oxide due to systemic inflammation and vascular dysfunction, resulting in a reduction in cGMP synthesis. Disruption in the nitric oxide-sGC-cGMP pathway results in issues in the regulation of myocardial and renal function, thus resulting in increased potential for myocardial damage.
LIST OF FIGURES
8 Figure 1: Vericiguat for chronic heart failure – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of vericiguat for chronic heart failure
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of vericiguat for chronic heart failure
12 Figure 4: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Vericiguat drug profile
6 Table 2: Vericiguat Phase III trials in chronic heart failure
7 Table 3: Vericiguat Phase II data in chronic heart failure
13 Table 4: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.